UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.717

Sortiert nach

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression

Journal of medicinal chemistry, 2018-01, Vol.61 (2), p.462-481

2018

Link zum Volltext

Verfügbarkeit prüfen

Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)

Journal of medicinal chemistry, 2019-02, Vol.62 (3), p.1420-1442

2019

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Novel Pyrrolo[2,3‑d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors

Journal of medicinal chemistry, 2022-01, Vol.65 (2), p.1243-1264

2022

Link zum Volltext

Verfügbarkeit prüfen

Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands

Journal of medicinal chemistry, 2018-01, Vol.61 (2), p.543-575

2018

Link zum Volltext

Verfügbarkeit prüfen

Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein

Journal of medicinal chemistry, 2020-07, Vol.63 (14), p.7510-7528

2020

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, and Biological Evaluation of Novel Selenium-Containing Isocombretastatins and Phenstatins as Antitumor Agents

Journal of medicinal chemistry, 2017-09, Vol.60 (17), p.7300-7314

2017

Link zum Volltext

Verfügbarkeit prüfen

Organometallic Gold(III) Complexes Similar to Tetrahydroisoquinoline Induce ER-Stress-Mediated Apoptosis and Pro-Death Autophagy in A549 Cancer Cells

Journal of medicinal chemistry, 2018-04, Vol.61 (8), p.3478-3490

2018

Link zum Volltext

Verfügbarkeit prüfen

An Update on Poly(ADP-ribose)polymerase‑1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy

Journal of medicinal chemistry, 2016-11, Vol.59 (21), p.9575-9598

2016

Link zum Volltext

Verfügbarkeit prüfen

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

Journal of medicinal chemistry, 2011-09, Vol.54 (18), p.6342-6363

2011

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Journal of medicinal chemistry, 2016-05, Vol.59 (10), p.4948-4964

2016

Link zum Volltext

Verfügbarkeit prüfen

Identification of (R)‑N‑((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)‑1H‑indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B‑Cell Lymphomas

Journal of medicinal chemistry, 2016-11, Vol.59 (21), p.9928-9941

2016

Link zum Volltext

Verfügbarkeit prüfen

Organometallic Half-Sandwich Iridium Anticancer Complexes

Journal of medicinal chemistry, 2011-04, Vol.54 (8), p.3011-3026

2011

Link zum Volltext

Verfügbarkeit prüfen

Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH)

Journal of medicinal chemistry, 2017-11, Vol.60 (22), p.9184-9204

2017

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, and Biological Evaluation of Stable Colchicine-Binding Site Tubulin Inhibitors 6-Aryl-2-benzoyl-pyridines as Potential Anticancer Agents

Journal of medicinal chemistry, 2021-08, Vol.64 (16), p.12049-12074

2021

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy

Journal of medicinal chemistry, 2021-12, Vol.64 (24), p.18025-18053

2021

Link zum Volltext

Verfügbarkeit prüfen

Mitochondria-Targeted Lupane Triterpenoid Derivatives and Their Selective Apoptosis-Inducing Anticancer Mechanisms

Journal of medicinal chemistry, 2017-07, Vol.60 (14), p.6353-6363

2017

Link zum Volltext

Verfügbarkeit prüfen

Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

Journal of medicinal chemistry, 2014-08, Vol.57 (16), p.6949-6964

2014

Link zum Volltext

Verfügbarkeit prüfen

Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents

Journal of medicinal chemistry, 2015-08, Vol.58 (16), p.6678-6696

2015

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, and Biological Evaluation of Novel Selenium (Se-NSAID) Molecules as Anticancer Agents

Journal of medicinal chemistry, 2016-03, Vol.59 (5), p.1946-1959

2016

Link zum Volltext

Verfügbarkeit prüfen

DNA-Unresponsive Platinum(II) Complex Induces ERS-Mediated Mitophagy in Cancer Cells

Journal of medicinal chemistry, 2022-01, Vol.65 (1), p.520-530

2022

Link zum Volltext

Verfügbarkeit prüfen

Integration of a Diselenide Unit Generates Fluorogenic Camptothecin Prodrugs with Improved Cytotoxicity to Cancer Cells

Journal of medicinal chemistry, 2021-12, Vol.64 (24), p.17979-17991

2021

Link zum Volltext

Verfügbarkeit prüfen

Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy

Journal of medicinal chemistry, 2018-10, Vol.61 (19), p.8754-8773

2018

Link zum Volltext

Verfügbarkeit prüfen

Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer

Journal of medicinal chemistry, 2022-02, Vol.65 (4), p.3404-3419

2022

Link zum Volltext

Verfügbarkeit prüfen

Quinazolinone-Based Anticancer Agents: Synthesis, Antiproliferative SAR, Antitubulin Activity, and Tubulin Co-crystal Structure

Journal of medicinal chemistry, 2018-02, Vol.61 (3), p.1031-1044

2018

Link zum Volltext

Verfügbarkeit prüfen

Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy

Journal of medicinal chemistry, 2012-05, Vol.55 (10), p.4527-4538

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.717

Suche als RSS-Feed

Aktive Filter

KollektionNexis Uni

Zeitschrift / SerieBioorganic & Medicinal Chemistry Letters

SpracheUkrainisch

Zeitschrift / SerieJournal Of Medicinal Chemistry

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.717)
Mit Volltextzugriff
(1.717)

Publikationsform

Artikel
(1.717)

Sprache

Englisch
(1.717)
Japanisch
(409)
Russisch
(2)

Erscheinungsjahr

n.n

Thema

Drug Screening Assays, Antitumor
(1.694)
Chemistry, Medicinal
(1.607)
Life Sciences & Biomedicine
(1.607)
Pharmacology & Pharmacy
(1.607)
Science & Technology
(1.607)
Humans
(1.586)
Structure-Activity Relationship
(1.400)
Antineoplastic Agents - Pharmacology
(1.382)
Antineoplastic Agents - Chemical Synthesis
(1.248)
Antineoplastic Agents - Chemistry
(1.123)
Cell Line, Tumor
(1.049)
Animals
(897)
Biological And Medical Sciences
(864)
Medical Sciences
(860)
Pharmacology. Drug Treatments
(835)
Antineoplastic Agents
(783)
General Aspects
(753)
Mice
(689)
Models, Molecular
(472)
Drug Discovery
(449)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(1.717)

Zeitschrift / Serie

Neu hinzugefügt

... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression

Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)

Discovery of Novel Pyrrolo[2,3‑d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors

Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands

Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein

Design, Synthesis, and Biological Evaluation of Novel Selenium-Containing Isocombretastatins and Phenstatins as Antitumor Agents

Organometallic Gold(III) Complexes Similar to Tetrahydroisoquinoline Induce ER-Stress-Mediated Apoptosis and Pro-Death Autophagy in A549 Cancer Cells

An Update on Poly(ADP-ribose)polymerase‑1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Organometallic Half-Sandwich Iridium Anticancer Complexes

Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH)

Design, Synthesis, and Biological Evaluation of Stable Colchicine-Binding Site Tubulin Inhibitors 6-Aryl-2-benzoyl-pyridines as Potential Anticancer Agents

Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy

Mitochondria-Targeted Lupane Triterpenoid Derivatives and Their Selective Apoptosis-Inducing Anticancer Mechanisms

Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents

Design, Synthesis, and Biological Evaluation of Novel Selenium (Se-NSAID) Molecules as Anticancer Agents

DNA-Unresponsive Platinum(II) Complex Induces ERS-Mediated Mitophagy in Cancer Cells

Integration of a Diselenide Unit Generates Fluorogenic Camptothecin Prodrugs with Improved Cytotoxicity to Cancer Cells

Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy

Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer

Quinazolinone-Based Anticancer Agents: Synthesis, Antiproliferative SAR, Antitubulin Activity, and Tubulin Co-crystal Structure

Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy

Aktive Filter

Suchergebnisse filtern